{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"6.1","value":"2.1"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"4.6","value":"2.2"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"4.0","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Progression is defined, per RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions (the sum must demonstrate an absolute increase of at least 5 mm), or the appearance of new lesions and/or unequivocal progression of non-target lesions.\n\nPFS will be summarized using Kaplan-Meier estimates. Will also assess PFS in patients stratified by PD-L1 expression levels in the tumor microenvironment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG000","title":"Group 1 (CYT107, Atezolizumab)"},{"description":"Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV","id":"OG001","title":"Group 2 (Atezolizumab)"},{"description":"Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG002","title":"Safety Run in Phase"}],"paramType":"MEDIAN","populationDescription":"Patients without documented PD or death are censored at the last disease assessment date.\n\nThe PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.","reportingStatus":"POSTED","timeFrame":"Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years.","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}